Core Viewpoint - The company, Tibet Duori Pharmaceutical Co., Ltd., has approved a cash management plan to utilize idle self-owned funds of up to 150 million yuan to enhance fund efficiency and achieve asset preservation and appreciation [1][2]. Investment Plan Details - The cash management plan is designed with the principles of prioritizing safety, matching liquidity, and supplementing returns, with a maximum investment amount of 150 million yuan and a strict investment period not exceeding 12 months [2]. - The funds will be invested in low-risk products issued by banks or other financial institutions, explicitly excluding stocks, derivatives, and unsecured bonds [3]. Funding Source and Decision Mechanism - The cash management funds will solely come from the company's idle self-owned funds, without involving raised or borrowed funds. The board has authorized management to make investment decisions within the set limits, with the finance department responsible for specific operations [4]. Risk Control and Supervision Mechanism - A multi-layered risk prevention system has been established, including a product selection mechanism that limits investments to low-risk products from state-owned banks or mainstream financial institutions, a dynamic monitoring mechanism for real-time tracking of product value changes, and an internal supervision mechanism for regular checks by independent directors and the supervisory board [5]. Impact on Company Operations - The cash management plan will not affect the company's main business operations, as it is implemented while ensuring the funding needs for daily production and project construction. The scientific allocation of idle funds is expected to enhance fund yield and further increase company profits, creating more value for shareholders [6]. Validity of the Resolution - The resolution is valid for 12 months from the date of board approval, with specific investment products to be selected based on market conditions [7].
多瑞医药拟斥资1.5亿元闲置自有资金开展现金管理 提升资金使用效率